Skip to content
Peptide research

GHRP-6

Also known as Growth Hormone Releasing Peptide 6 · SKF-110679
Category
Growth Hormone
Administration routes
Injectable
Regulatory status
Not FDA-approved

What it is

A synthetic six-amino-acid peptide that spikes growth hormone via the ghrelin receptor, marketed for muscle gain, recovery, and appetite. Higher GH and IGF-1 are its dependable effects, while claims of heart and organ protection rest only on animal and mechanism data. It drives the strongest hunger of any GHRP, can raise cortisol and blood sugar, with no long-term human safety data. Not FDA-approved; unregulated products sold online vary in purity.

Read Full record

Studied uses & evidence

Studied uses(7)

  • Potent GH release

    High

    Human crossover trials confirm strong GH release, exceeding GHRH alone and synergistic when combined.

  • Cardioprotection

    Low

    Animal studies in rats, pigs, and dogs show protection against heart damage; no human trials yet.

  • Cytoprotection (multi-organ)

    Low

    Rat ischemia-reperfusion models show liver, kidney, lung, and gut protection; no human data.

Evidence limits

Evidence Level
Mostly Preclinical

Extensive preclinical evidence for GH secretion, cardioprotection, and cytoprotection across multiple organ systems. Human studies limited to GH-stimulation tests (healthy volunteers and children with short stature), diagnostic use for pituitary reserve evaluation, and comparative studies in Cushing's disease. Oral GHRP-6 (300 mcg/kg) shown effective in children. A Phase III trial of GHRP-6 combined with EGF in 188 stroke patients missed its primary endpoint. This does not establish efficacy of GHRP-6 alone; cardiac and multi-organ protection remain preclinical.

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

Do not use if

  • Active cancer

    High

    GH secretagogue — promotes tumor growth via GH/IGF-1.

  • Eating disorders

    High

    GHRP-6 causes intense hunger through ghrelin activation. Problematic for binge eating.

  • Diabetic retinopathy

    High

    GH/IGF-1 elevation can worsen retinal neovascularization.

  • Diabetes/insulin resistance

    Moderate

    GH elevation can worsen blood sugar control and insulin sensitivity.

Risk summary(6)

Risks = level of concern: High · Moderate · Low · Theoretical

  • Intense appetite stimulation (strongest among GHRPs)

    High
  • Cortisol and ACTH elevation (non-selective GHS-R activation)

    Moderate
  • Prolactin elevation; potential gynecomastia with chronic use

    Low
  • Water retention and joint discomfort from GH/IGF-1

    Low
  • Blood glucose effects; potential insulin resistance

    Moderate
  • No long-term human safety data

    High
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.